BRCTF 財務： BioArctic AB (publ) AI 分析

首頁

股票

BRCTF

財務狀況

BRCTF 財務

BioArctic AB (publ)

$33.02

收盤價：Mar 26, 16:00:00 GMT-4

$33.02

盤後：Mar 26, 17:16:23 GMT-4

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

BRCTF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
營收	1,999	1,999	257	615	228	23
營收年增率 (YoY)	678%	678%	-57.99%	170%	891%	-63%
營收成本	59	59	26	50	33	24
毛利	1,939	1,939	230	565	195	-1
銷售、一般及管理費用	194	194	148	200	115	72
研發	376	376	311	--	--	--
營業費用	681	681	452	300	203	139
其他非營業收入 (費用)	0	0	0	0	0	0
稅前淨利	1,255	1,255	-189	276	-11	-140
所得稅費用	233	233	-12	47	0	-20
淨利	1,022	1,022	-177	229	-11	-119
淨利成長	-677%	-677%	-177%	-2,182%	-91%	75%
稀釋後流通股數	88.28	88.74	88.34	88.48	85.99	88.06
股數年變動 (YoY)	0%	0%	0%	3%	-2%	0%
每股盈餘 (稀釋)	11.58	11.52	-2	2.59	-0.13	-1.36
每股盈餘成長率	-678%	-675%	-177%	-2,093%	-90%	75%
自由現金流	1,431	1,431	-342	302	-44	-144
每股自由現金流	--	--	--	--	--	--
毛利率	96.99%	96.99%	89.49%	91.86%	85.52%	-4.34%
營業利益率	62.93%	62.93%	-86.38%	42.92%	-3.07%	-608.69%
淨利率	51.12%	51.12%	-68.87%	37.23%	-4.82%	-517.39%
自由現金流利潤率	71.58%	71.58%	-133.07%	49.1%	-19.29%	-626.08%
EBITDA	1,270	1,270	-212	271	7	-127
EBITDA 利潤率	63.53%	63.53%	-82.49%	44.06%	3.07%	-552.17%
EBITDA 中的折舊與攤銷	12	12	10	7	14	13
EBIT	1,258	1,258	-222	264	-7	-140
EBIT 利潤率	62.93%	62.93%	-86.38%	42.92%	-3.07%	-608.69%
有效稅率	18.56%	18.56%	6.34%	17.02%	0%	14.28%

Follow-Up Questions

BioArctic AB (publ) 的關鍵財務報表是什麼？



根據最新的財務報表（Form-10K），BioArctic AB (publ) 的總資產為 $2,575，淨isProfitable}為 $1,022

BRCTF 的關鍵財務比率是什麼？



BioArctic AB (publ) 的流動比率為 4.23，淨利潤率為 51.12，每股銷售為 $22.52。

BioArctic AB (publ) 的收入按細分市場或地理位置如何劃分？



BioArctic AB (publ) 最大收入來源為 Innovative Biological Drugs，在最近的收益報告中收入為 257,351,999。就地區而言，North America 是 BioArctic AB (publ) 的主要市場，收入為 144,515,000。

BioArctic AB (publ) 是否盈利？



是的，根據最新的財務報表，BioArctic AB (publ) 的淨利潤為 $1,022

BioArctic AB (publ) 有負債嗎？



是的，BioArctic AB (publ) 的負債為 608

BioArctic AB (publ) 的流通股有多少？



BioArctic AB (publ) 的總流通股為 88.63

關鍵數據

前收市價

$33.02

開盤價

$38

當日範圍

$33.02 - $38

52週區間

$15.49 - $38.06

交易量

200

平均成交量

股息收益率

每股盈餘 (TTM)

1.24

市值

$2.4B

什麼是 BIOARCTIC AB？

BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 122 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.

功能特性

資源